Cefiderocol Activity in Resistant European Non-Fermenters

Carbapenem-resistant non-fermenting Gram-negative bacteria are difficult to treat because resistance can combine reduced permeability, active efflux, β-lactamase production, and changes in target or uptake pathways. The reference study by Santerre Henriksen and colleagues addresses this problem with a large, geographically distributed comparison of cefiderocol and several β-lactam/β-lactamase inhibitor combinations. Its value lies not only in the overall susceptibility percentages, but also in the deliberate inclusion of isolates resistant to meropenem and recently introduced combination agents.

The findings should be read as surveillance and in vitro evidence. They indicate how cefiderocol performed against a challenging European isolate collection and identify genetic features associated with cefiderocol resistance; they do not establish comparative clinical efficacy for individual patients.

Study Background and Research Question

The study was motivated by the limited treatment options for carbapenem-resistant P. aeruginosa and Acinetobacter spp. These organisms are particularly important in hospital respiratory and other invasive infections, where resistance to established antipseudomonal agents can leave clinicians with few active drugs. The investigators asked whether cefiderocol maintained activity against contemporary European isolates, including those resistant to high-dose meropenem and to β-lactam/β-lactamase inhibitor combinations used or considered for difficult-to-treat infections.

A second question concerned cross-resistance. If an isolate is resistant to meropenem, ceftazidime-avibactam, or another advanced β-lactam combination, does it also tend to be resistant to cefiderocol? The study further examined the molecular basis of cefiderocol resistance, focusing on acquired β-lactamase genes and mutations in genes associated with siderophore-antibiotic uptake. These questions are clinically relevant because susceptibility to one advanced β-lactam does not necessarily predict susceptibility to another.

Key Innovation from the Reference Study

The principal innovation was a direct, head-to-head in vitro comparison using a notably large European collection and a resistance-focused analysis. The authors tested cefiderocol alongside multiple β-lactam/β-lactamase inhibitor combinations against the same non-fermenting Gram-negative population. According to the reference study, this was the first investigation to make this direct comparison across P. aeruginosa and Acinetobacter spp. while deliberately evaluating isolates resistant to meropenem and newer combinations.

Another important design choice was the definition of meropenem resistance. The investigators used an MIC greater than 8 mg/L, corresponding to the breakpoint for high-dose meropenem. This avoids presenting isolates as susceptible merely because a lower-dose breakpoint was applied, and makes the resistant subset more relevant to situations in which high-dose meropenem would still be unlikely to provide reliable activity.

The molecular component also strengthened the study. PCR was used for meropenem-resistant, cefiderocol-susceptible isolates, whereas whole-genome sequencing was applied to cefiderocol-resistant isolates. This allowed the authors to distinguish broad susceptibility patterns from specific genetic associations and to explore whether β-lactamase acquisition alone explained cefiderocol resistance.

Methods and Experimental Design Insights

Non-fermenting Gram-negative isolates were collected from hospitalized inpatients at 49 sites in six European countries during the period from 1 January through 31 December 2020. The collection comprised 1,451 isolates: 950 P. aeruginosa and 501 Acinetobacter spp. Respiratory specimens were common, accounting for 42.0% of the P. aeruginosa collection and 39.3% of the Acinetobacter collection, according to the published dataset.

Susceptibility testing covered cefiderocol and a panel of β-lactam/β-lactamase inhibitor combinations. The analysis was structured in several layers:

• Overall population: Compare cefiderocol susceptibility with the available combination therapies across all collected P. aeruginosa and Acinetobacter spp.
• Meropenem-resistant subset: Apply the MIC greater than 8 mg/L definition to identify isolates that remained resistant even under the high-dose meropenem criterion.
• Combination-resistant subsets: Examine isolates resistant to ceftazidime-avibactam, ceftolozane-tazobactam, sulbactam-durlobactam, or other tested combinations.
• Genetic follow-up: Use PCR or whole-genome sequencing to investigate β-lactamase genes and mutations potentially affecting cefiderocol uptake or activity.

Protocol Parameters

• Collection window: Use the 1 January to 31 December 2020 interval as the literature-backed surveillance period when reproducing the study framework; a new project should define its own contemporary sampling window.
• Geographic sampling: The reference design covered 49 hospital sites in six European countries. Replication should preserve site-level metadata so regional differences are not confused with organism-level resistance.
• Isolate composition: The study included 950 P. aeruginosa and 501 Acinetobacter spp. isolates. A local workflow should report species identification and specimen source separately rather than pooling all non-fermenters.
• Meropenem resistance threshold: Classify the high-dose meropenem-resistant group at MIC greater than 8 mg/L, as specified in the reference study; laboratories should verify current standards before applying the threshold.
• Genomic triage: PCR was used for meropenem-resistant, cefiderocol-susceptible isolates, while cefiderocol-resistant isolates underwent whole-genome sequencing. This tiered design can help allocate sequencing resources to the most informative isolates.

For a new surveillance program, the most transferable lesson is the separation of phenotypic testing from mechanistic interpretation. Susceptibility results should be retained with isolate origin, species, prior resistance phenotype, and genomic data whenever possible. That structure makes it easier to identify genuine cross-resistance patterns and to test whether a candidate mutation is consistently associated with resistance.

Core Findings and Why They Matter

Against P. aeruginosa, cefiderocol showed 98.9% susceptibility, compared with 83.3% to 91.4% for the tested β-lactam/β-lactamase inhibitor combinations. The difference became more pronounced among the 139 meropenem-resistant isolates: cefiderocol susceptibility was 97.8%, whereas the comparator range was 12.2% to 59.7%. These results suggest that meropenem resistance was not a dependable surrogate for cefiderocol resistance in this collection.

The same pattern was observed among isolates resistant to advanced combinations. For P. aeruginosa resistant to both meropenem and ceftazidime-avibactam, cefiderocol susceptibility was 96.7%, compared with 5.0% to 45.0% for the comparator agents. In isolates resistant to both meropenem and ceftolozane-tazobactam, cefiderocol susceptibility was 98.4%, while comparator susceptibility ranged from 8.1% to 54.8%. The study results therefore support testing cefiderocol independently rather than inferring its activity from resistance to another β-lactam.

Activity against Acinetobacter spp. was also substantial, although the comparison differed from that in P. aeruginosa. Cefiderocol susceptibility was 92.4%, while sulbactam-durlobactam susceptibility was 97.0%. Among 227 meropenem-resistant Acinetobacter isolates, cefiderocol susceptibility was 85.0% and sulbactam-durlobactam susceptibility was 93.8%. Thus, cefiderocol remained active against most resistant isolates, but its performance was not uniformly superior across species or comparator classes.

The resistant subsets were especially informative. Among meropenem-resistant P. aeruginosa, metallo-β-lactamases were the most common β-lactamase category, with bla_VIM-2 detected in 15 of 139 isolates. In meropenem-resistant Acinetobacter spp., oxacillinases predominated: 215 of 227 isolates carried an acquired β-lactamase gene, including 194 with bla_OXA-23. These distributions reinforce the importance of species-specific resistance biology.

Genomic analysis also pointed to uptake-related mechanisms. Acquired β-lactamase genes were found in 1 of 10 cefiderocol-resistant P. aeruginosa isolates and 32 of 38 cefiderocol-resistant Acinetobacter isolates. In contrast, pirA-like or piuA-associated mutations were identified in 10 of 10 and 37 of 38 isolates, respectively. The association is consistent with a role for siderophore transport pathways, but it should not be interpreted as proof that every mutation is independently causal.

Overall, the study found no apparent broad cross-resistance between cefiderocol and the β-lactam/β-lactamase inhibitor combinations, with sulbactam-durlobactam in Acinetobacter being the notable exception. Practically, the data support early parallel susceptibility testing when several advanced agents may be options.

Comparison with Existing Internal Articles

The internal article Applied Workflows for Gram-Negative Resistance Research is oriented toward translating resistance literature into laboratory workflows. It complements the reference study by emphasizing experimental organization, but it should not be treated as an independent validation of the cefiderocol susceptibility percentages reported here.

A second resource, Mechanistic Leverage in Translational Resistance Research, provides a broader discussion of mechanism and translational interpretation. Its relationship to this paper is conceptual: both emphasize that resistance phenotype, genetic mechanism, and treatment selection should be analyzed together. The reference study remains the appropriate source for the European isolate counts, susceptibility comparisons, and genomic associations.

Limitations and Transferability

Several limitations constrain interpretation. First, this was an in vitro surveillance study rather than a randomized clinical trial. A high susceptibility rate does not guarantee clinical success, because dosing, infection site, bacterial burden, host factors, and pharmacokinetic exposure also influence treatment outcomes. Second, the isolates were collected in six European countries during 2020. Resistance distributions can change over time and may differ substantially in other regions, hospitals, or patient populations.

Third, the Acinetobacter category was reported as Acinetobacter spp., so pooled results may conceal species-level differences. Fourth, the molecular analysis focused on selected subsets and identified associations rather than experimentally proving the function of each β-lactamase gene or pirA-like/piuA alteration. Functional complementation, expression analysis, and carefully controlled MIC experiments would be needed to establish causality.

Finally, interpretation should account for the study’s disclosed relationships with pharmaceutical companies and organizations involved in antimicrobial reporting. The disclosures do not invalidate the findings, but independent laboratories and longitudinal surveillance remain important for confirming the observed resistance patterns.

Research Support Resources

Researchers can use Aztreonam (SKU A5931) as a separately characterized comparator in Gram-negative resistance workflows. This monocyclic β-lactam antibiotic is described in the product information as having antibiotic activity against Gram-negative aerobic bacteria through inhibition of bacterial cell wall synthesis. Any comparator experiment should use a validated susceptibility method and should not substitute product activity data for the cefiderocol-specific evidence in the reference study.

Why this cross-domain matters, maturity, and limitations

The product information also reports bone marrow progenitor cell inhibition and effects on liver cytochrome P450 enzymes in separate experimental models. Those observations may be relevant when a resistance workflow is extended into pharmacology, toxicology, or host-cell assays, but they are outside the scope of the European bacterial surveillance study and should not be used to infer clinical toxicity or cefiderocol mechanism. The cross-domain evidence is therefore useful for hypothesis generation, while species-specific susceptibility testing and independently controlled mammalian assays remain necessary for confirmation.

For practical handling, the product is supplied as a solid and should be stored according to the linked product documentation; solutions are intended for short-term use. This resource is for scientific research use only, not for diagnostic or medical purposes.